2025 update of EULAR recommendations on lupus nephritis At the 2025 EULAR congress in Barcelona, Prof Dimitrios Boumpas presented updated EULAR recommendations on managing lupus nephritis (LN). The key change is that the historic standard of care (mycophenolate with https://t.co/K3s1RIpEES

Rheumatoid arthritis incidence has risen to 17.9 million people globally -13.2% increase from 1990-2021. Fewer people are dying from RA, but disability-adjusted life Yrs have doubled. high sociodemographic index bore the heaviest burden. Smoking control policies is forecasted to https://t.co/YmWcinVdmE

#EULAR2025 TriNetX database study indicated that fibromyalgia patients who used glucagon-like peptide-1 (GLP-1) receptor agonist drugs were less likely to use opioids and to report pain, fatigue, and malaise compared with propensity-matched non-users https://t.co/ftm93VwW65 https://t.co/2wloutoX8a

• GLP-1 Drugs May Help in Fibromyalgia, Large Records Study Suggests

Predictors and Outcomes in Systemic Sclerosis The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will https://t.co/C4Pro6b0Jw

Expanding the IL-17 Therapeutic Landscape IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. https://t.co/Q7Thp1HJAL

Putting IL17i into ‘focus’ for SpA-associated uveitis The longest studied drug for uveitis in SpA has been monocolonal TNFi Abs. Reductions of acute anterior uveitis have been found with etanercept but less impressively than adalimumab, infliximab, and in my opinion less than https://t.co/AUEct0FxmU

Psoriatic Arthritis: Hit hard and Early Two studies found no significant benefit of early biologics over standard methotrexate treatment, but they did not focus on poor prognosis cases. The SPEED trial, funded by the NIHR, aimed to compare disease activity in 192 PsA patients https://t.co/pS9DdOOVCV

The Value of Kidney Biopsy in Autoimmune Diseases Dr. Andrea Fava shares his perspective from the EULAR 2025 meeting in Barcelona, Spain. https://t.co/CA6Ak2scKb https://t.co/EK5wdpbzrl

• The Value of Kidney Biopsy in Autoimmune Diseases | RheumNow

EULAR Daily Recap: Day 3 Catch up on the biggest breakthroughs, standout sessions, and expert insights from day three of EULAR 2025. Listen to panelists break down the key highlights and what they mean for the future of rheumatology. Panelists: Drs. Yuz Yusof, Aurelie Najm, https://t.co/jmXUDV8odR

ALTO: Long-term Outcomes of APIPPRA Dr. Mrinalini Dey interviews Professor Andrew Cope about abstract OP0004, on the long term outcome of APIPPRA patients - the ALTO study, at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/9wVZSXbi6r https://t.co/fm77qDoTwm

• ALTO: Long-term Outcomes of APIPPRA | RheumNow

EULAR 2025 – Day 4 Report Saturday was the final day of EULAR, and included several lectures, but mostly late breaking abstracts and new EULAR guidelines - notably on Rheumatoid Arthritis and another on Interstitial Lung disease in connective tissue disorders. https://t.co/ZJ1pHQJTbK

Toward Long-Term Prevention of Rheumatoid Arthritis: Are We Closer? As earlier diagnosis and treatment of rheumatoid arthritis (RA) have resulted in greatly improved clinical outcomes, the focus of current research has now shifted to preventing the development of RA altogether. https://t.co/HGbXVLVuSC

Difficult to Treat Axial Spondyloarthritis Drs. Antoni Chan and Martina Magrey discuss abstract POS0117 presented at the 2025 EULAR meeting in Barcelona. https://t.co/isv05fzV1d https://t.co/Ji24s9qSZF

• https://buff.ly/TNqTwBK